In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

KAMPALA - Dr Matthias Magoola says the US Patent and Trademark Office (USPTO) has granted a patent for his invention of the first treatment of cancer using a novel composition of a guided Ribonucleic ...

近日，厦门大学生命科学学院刘亮教授团队在《Nucleic Acids Research》期刊上在线发表了题为“DNA target binding-induced pre-crRNA processing in type II and V CRISPR-Cas ...

The EU CRISPR patent landscape: a complex battle In the patent field, CRISPR/Cas technology has sparked intense patent battles in Europe, with significant implications for innovation and market ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and ...

It would also essentially consolidate most of the CRISPR/Cas9 patents, hopefully curbing future litigation and saving royalties. The market cap of Editas, however, would indicate that the value of ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

The pharmaceutical industry remains a hub of patent innovation ... its way into clinical trials in the mid-2000s. In 2014, ...

License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services. ERS Genomics Limited has announced a new license agreement with ...

ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...